MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2023.1204444

Медицинская библиотека · Frontiers in immunology · 2023

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.

Nolasco Santi, Portacci Andrea, Campisi Raffaele, Buonamico Enrico, Pelaia Corrado, Benfante Alida, Triggiani Massimo, Spadaro Giuseppe, Caiaffa Maria Filomena, Scioscia Giulia, Detoraki Aikaterini, Valenti Giuseppe, Papia Francesco, Tomasello Alessandra, Crimi Nunzio, Scichilone Nicola, Pelaia Girolamo, Carpagnano Giovanna Elisiana, Crimi Claudia

Многоцентровое исследованиеНаблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.

OBJECTIVE

To assess the effectiveness and safety of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in EGPA for 24 months.

METHODS

We conducted a multicenter observational study, including patients with EGPA treated with anti-IL-5/Rα biologics in 9 Italian specialized facilities. Systemic disease activity, remission and relapse rate were evaluated from 3 to 24 months after treatment initiation. Respiratory outcomes, hematological parameters, corticosteroid (OCS) and immunosuppressants consumption were also assessed.

RESULTS

49 patients with relapsing-refractory EGPA were included [26 (53.1%) benralizumab 30mg, 20 (40.8%) mepolizumab 100mg, 3 (6.1%) mepolizumab 300mg]. Overall, 38.8% and 57.1% achieved remission after 12 and 24 months, respectively (69.2% benralizumab and 43.5% mepolizumab). Lower OCS intake and higher blood eosinophil count at baseline were associated with remission at 24 months. Both biologics exerted beneficial effects on severe asthma outcomes. Indeed, 61.2% (61.5% benralizumab and 60.8% mepolizumab) remained exacerbation-free during treatment. Lung function parameters showed improvements in the overall cohort (all p<0.05), but began to decline from month 12, especially with mepolizumab. Marked reduction in blood eosinophils was registered with mepolizumab (p<0.0001), while benralizumab depleted both eosinophils (p<0.0001) and basophils (p<0.0001). In general, 69.6% (76% benralizumab and 61.9% mepolizumab) of OCS-dependent patients lowered their daily dose by 75%, while 28.3% discontinued these drugs. Immunosuppressants were suspended in 88.2% of cases. Adverse events were reported in 8.2% of patients.

CONCLUSIONS

These real-world data suggest that anti-IL-5/Rα biologics are effective and safe in the long-term as add-on treatments for patients with EGPA.

Для цитирования: Nolasco Santi, Portacci Andrea, Campisi Raffaele, Buonamico Enrico, Pelaia Corrado, Benfante Alida, Triggiani Massimo, Spadaro Giuseppe, Caiaffa Maria Filomena, Scioscia Giulia, Detoraki Aikaterini, Valenti Giuseppe, Papia Francesco, Tomasello Alessandra, Crimi Nunzio, Scichilone Nicola, Pelaia Girolamo, Carpagnano Giovanna Elisiana, Crimi Claudia. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.. Frontiers in immunology. 2023. DOI: 10.3389/fimmu.2023.1204444.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.